Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc (NQ: XENE )

37.12 -0.92 (-2.42%)
Streaming Delayed Price Updated: 11:42 AM EDT, Jun 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Xenon Pharmaceuticals Inc

< Previous 1 2 3 4 Next >
Mid-Afternoon Market Update: Dow Drops 375 Points; Elmira Savings Bank Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 1.09% to 33,951.17 while the NASDAQ fell 2.28% to 14,234.17. The S&P also fell, dropping 1.49% to 4,292.00. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
XENE Stock: The Huge FDA News Sending Xenon Pharmaceuticals to the Moon
Here's why investors in clinical-stage biotech stock Xenon Pharmaceuticals are cheering today as XENE stock runs wild. 
Via InvestorPlace
Exposures Product Safety
Mid-Day Market Update: Nasdaq Down 2%; Xenon Pharmaceuticals Shares Jump
Midway through trading Monday, the Dow traded down 1.02% to 33,976.93 while the NASDAQ fell 2.14% to 14,255.08. The S&P also fell, dropping 1.23% to 4,303.43. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
30 Stocks Moving In Monday's Mid-Day Session
Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares jumped 71.1% to $26.69 after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For May 11, 2021
Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth quarter. • ReWalk Robotics (NASDAQ:RWLK) is... 
Via Benzinga
Xenon Pharma Shares Jump After Epilepsy Treatment Phase 2 Data Meets Primary Endpoint
Xenon Pharmaceuticals Inc (NASDAQ: XENE) has reported topline results from the Phase 2b X-TOLE trial evaluating XEN1101 as an adjunctive treatment in adult... 
Via Benzinga
Mid-Morning Market Update: Markets Mostly Lower; US Factory Orders Surpass Estimates
Following the market opening Monday, the Dow traded down 0.01% to 34,326.18 while the NASDAQ fell 1.4% to 14,362.69. The S&P also fell, dropping 0.51% to 4,334.77. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Xenon Pharmaceuticals Stock Is Soaring Today
Xenon Pharmaceuticals Inc (NASDAQ: XENE) is trading significantly higher Monday after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all... 
Via Benzinga
Why Xenon Pharmaceuticals Stock Is Screaming Higher Today
A positive mid-stage trial is powering this biotech stock higher today. 
Via The Motley Fool
Xenon Pharmaceuticals Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Xenon Pharmaceuticals (NASDAQ:XENE) reported Q2 sales of $2.22 million. Earnings fell to a loss of $22.50 million, resulting in a 40.1% decrease from last... 
Via Benzinga
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For August 11, 2021
Companies Reporting Before The Bell • Wireless Telecom Group (AMEX:WTT) is likely to report earnings for its second quarter. • Gamida Cell (NASDAQ:GMDA) is... 
Via Benzinga
18 Key Biopharma Catalysts To Keep An Eye On In Q3
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Here is a look at some catalysts for the biopharam sector in the... 
Via Talk Markets
18 Key Biopharma Catalysts To Keep An Eye On In Q3
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Ne... 
Via Benzinga
Return On Capital Employed Overview: Xenon Pharmaceuticals
In Q1, Xenon Pharmaceuticals (NASDAQ:XENE) posted sales of $4.36 million. Earnings were up 24.27%, but Xenon Pharmaceuticals still reported an overall loss of $16.06 million. In... 
Via Benzinga
Looking Into Xenon Pharmaceuticals's Return On Capital Employed
During Q1, Xenon Pharmaceuticals's (NASDAQ:XENE) reported sales totaled $4.36 million. Despite a 24.27% in earnings, the company posted a loss of $16.06 million. In Q4, Xenon... 
Via Benzinga
Xenon Pharmaceuticals's Earnings Outlook
Xenon Pharmaceuticals (NASDAQ:XENE) announces its next round of earnings this Tuesday, May 11. Here is Benzinga's everything-that-matters guide for this Tuesday's Q1 earnings... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.